天宇股份 reported revenue of ¥2.01B for the period ended 2026-06-30, +13.2% year on year. Net income was ¥0.10B, a 5.2% net margin on a 30.1% gross margin. The largest revenue line is 仿制药原料药及中间体 at 68% of the total. Free cash flow for the period was ¥0.24B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.01B | +13.2% |
| Gross profit | ¥0.61B | — |
| Operating income | ¥0.13B | — |
| Net income | ¥0.10B | -34.0% |
| Gross margin | 30.1% | Net margin 5.2% |
| Revenue Q/Q | +47.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 仿制药原料药及中间体 | ¥1.37B | 68.3% |
| 制剂 | ¥0.28B | 13.9% |
| 高纯溶剂 | ¥0.21B | 10.3% |
| CDMO原料药及中间体 | ¥0.10B | 5.2% |
| 其他 | ¥0.05B | 2.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.40B | 69.9% |
| R&D | ¥0.12B | 6.2% |
| SG&A | ¥0.28B | 13.8% |
| Tax & other | ¥0.03B | 1.3% |
| Item | Amount |
|---|---|
| Total assets | ¥6.89B |
| Total liabilities | ¥3.28B |
| Shareholders' equity | ¥3.61B |
| Equity / assets | 52.3% |
| Operating cash flow | ¥0.28B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥0.24B |
| Cash conversion (OCF / net income) | 397% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
创源股份 ・ 九典制药 ・ 阿石创 ・ 威唐工业 ・ 聚灿光电 ・ 精研科技 ・ 万隆光电 ・ 广哈通信 ・ 永福股份 ・ 英可瑞 ・ 凯伦股份 ・ *ST泉为
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies